Next, we validated the platform with an established chronic myeloid leukemia (CML) fusion gene (BCR-ABL1) assay down to 0.01% mutant allele frequency to highlight the platform’s utility for precision cancer monitoring. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.